Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Circulating tumor cells and emerging blood biomarkers in breast cancer

Circulating tumor cells and emerging blood biomarkers in breast cancer Circulating tumor cells and emerging blood biomarkers in breast cancer a,b a,b a,b Carmen Criscitiello , Christos Sotiriou and Michail Ignatiadis a b Medical Oncology Department and Breast Cancer Purpose of review Translational Research Laboratory, Jules Bordet To critically review the latest findings concerning the role of circulating tumor cells Institute, 121 Boulevard de Waterloo, Brussels, Belgium (CTCs) and other blood biomarkers in breast cancer. Recent findings Correspondence to Michail Ignatiadis, MD, PhD, Medical Oncology Department and Breast Cancer CTCs are epithelial tumor cells detected in the peripheral blood of patients with solid Translational Research Laboratory, Jules Bordet tumors using mainly cytometric/antibody-based and molecular approaches. Most Institute, 121 Boulevard de Waterloo, 1000 Brussels, Belgium technologies for CTC detection, including the FDA-approved CellSearch, are only Tel: +32 2 541 72 81; fax: +32 2 538 08 58; detecting epithelial cell adhesion molecule (EpCAM)-positive CTCs and may miss e-mail: Michail.Ignatiadis@bordet.be clinically relevant subpopulations of CTCs. The value of CTC detection by CellSearch in Current Opinion in Oncology 2010, 22:552–558 metastatic breast cancer (MBC) may depend on the clinical setting and regimen used. In a retrospective analysis of 516 patients with MBC, CTC detection did not predict clinical outcome in chemo-naı¨ve women http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Oncology Wolters Kluwer Health

Circulating tumor cells and emerging blood biomarkers in breast cancer

Current Opinion in Oncology , Volume 22 (6) – Nov 1, 2010

Loading next page...
 
/lp/wolters-kluwer-health/circulating-tumor-cells-and-emerging-blood-biomarkers-in-breast-cancer-ojCWsosUS2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1040-8746
eISSN
1531-703X
DOI
10.1097/CCO.0b013e32833de186
pmid
20706122
Publisher site
See Article on Publisher Site

Abstract

Circulating tumor cells and emerging blood biomarkers in breast cancer a,b a,b a,b Carmen Criscitiello , Christos Sotiriou and Michail Ignatiadis a b Medical Oncology Department and Breast Cancer Purpose of review Translational Research Laboratory, Jules Bordet To critically review the latest findings concerning the role of circulating tumor cells Institute, 121 Boulevard de Waterloo, Brussels, Belgium (CTCs) and other blood biomarkers in breast cancer. Recent findings Correspondence to Michail Ignatiadis, MD, PhD, Medical Oncology Department and Breast Cancer CTCs are epithelial tumor cells detected in the peripheral blood of patients with solid Translational Research Laboratory, Jules Bordet tumors using mainly cytometric/antibody-based and molecular approaches. Most Institute, 121 Boulevard de Waterloo, 1000 Brussels, Belgium technologies for CTC detection, including the FDA-approved CellSearch, are only Tel: +32 2 541 72 81; fax: +32 2 538 08 58; detecting epithelial cell adhesion molecule (EpCAM)-positive CTCs and may miss e-mail: Michail.Ignatiadis@bordet.be clinically relevant subpopulations of CTCs. The value of CTC detection by CellSearch in Current Opinion in Oncology 2010, 22:552–558 metastatic breast cancer (MBC) may depend on the clinical setting and regimen used. In a retrospective analysis of 516 patients with MBC, CTC detection did not predict clinical outcome in chemo-naı¨ve women

Journal

Current Opinion in OncologyWolters Kluwer Health

Published: Nov 1, 2010

There are no references for this article.